Stewart W. Strong - 07 Jun 2023 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
President, Global Hospital
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Strong
Issuer symbol
HAE
Transactions as of
07 Jun 2023
Net transactions value
-$275,690
Form type
4
Filing time
09 Jun 2023, 16:16:06 UTC
Previous filing
19 May 2023
Next filing
13 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Options Exercise $253,603 +4,483 +26% $56.57 21,630 07 Jun 2023 Direct F1
transaction HAE Common Stock Options Exercise $138,816 +2,410 +11% $57.60 24,040 07 Jun 2023 Direct F1
transaction HAE Common Stock Tax liability $444,664 -5,053 -21% $88.00 18,987 07 Jun 2023 Direct F1, F2
transaction HAE Common Stock Sale $223,446 -2,538 -13% $88.04 16,449 07 Jun 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -4,483 -50% $0.000000 4,483 07 Jun 2023 Common Stock 4,483 $56.57 Direct F4
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -2,410 -25% $0.000000 7,231 07 Jun 2023 Common Stock 2,410 $57.60 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This number includes unvested restricted stock units ("RSUs") previously reported.
F2 Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.96 to $88.12, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this report.
F4 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.